Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide-based treatment in transplant-ineligible newly diagnosed multiple myeloma
2021-002190-25Phase 2Active
- Sponsor
- PETHEMA
- Start
- Feb 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of iberdomide, dexamethasone and daratumumab in multiple myeloma (MM) (2 cohorts), sponsored by PETHEMA. Primary endpoints: Overall response rate and Complete response rate. Started Feb 2022; status: active.
02
Drugs
iberdomidedexamethasonedaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2021-002190-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002190-25.